Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 1;5:PO.20.00445. doi: 10.1200/PO.20.00445

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 5. — Association of PFS with genes relevant to the estrogen receptor pathway: (A) PFS by GATA3 alteration status and (B) PFS by MYC alteration status. Kaplan-Meier curves of PFS in patients who exhibited alterations in the indicated genes in circulating tumor DNA. PFS in patients in the ribociclib treatment arm is shown in red; in patients in the placebo treatment arm, it is shown in blue. The WT subgroup is indicated by a solid line, and the alteration subgroup is indicated by a dashed line. HR (95% CI) estimates and median PFS (95% CI) values are shown in the corresponding tables. Alt, altered; HR, hazard ratio; NA, not achieved; PBO, placebo; PFS, progression-free survival; RIB, ribociclib; WT, wild-type.